Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.

ABSTRACT:

Purpose

Although most patients with estrogen receptor (ER)-positive breast cancer benefit from endocrine therapies, a significant proportion do not. Our aim was to identify inherited genetic variations that might predict survival among patients receiving adjuvant endocrine therapies.

Experimental design

We performed a meta-analysis of two genome-wide studies; Helsinki Breast Cancer Study, 805 patients, with 240 receiving endocrine therapy and Prospective study of Outcomes in Sporadic versus Hereditary breast cancer, 536 patients, with 155 endocrine therapy patients, evaluating 486,478 single-nucleotide polymorphisms (SNP). The top four associations from the endocrine treatment subgroup were further investigated in two independent datasets totaling 5,011 patients, with 3,485

SUBMITTER: Khan S 

PROVIDER: S-EPMC4574404 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature